NYSE · TMO
Healthcare · Medical - Diagnostics & Research
$618.43
Down-$3.88 (-0.63%)
Updated Sep 4, 2026, 4:31 PM
SID Score
7.1/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
TMO closed at $618.43 after 21 trading sessions, up 6.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $614.03 | $622.91 | $603.52 | $618.43 | 1.8M |
| Sep 2, 2026 | $601.63 | $614.5975 | $600.70 | $608.54 | 1.62M |
| Sep 1, 2026 | $619.00 | $621.00 | $599.52 | $600.50 | 1.39M |
| Aug 31, 2026 | $614.38 | $620.715 | $610.35 | $617.10 | 1.43M |
| Aug 28, 2026 | $626.58 | $630.00 | $617.45 | $622.18 | 1.02M |
| Aug 27, 2026 | $629.47 | $637.13 | $626.33 | $630.70 | 1.47M |
| Aug 26, 2026 | $622.23 | $636.06 | $622.23 | $633.71 | 1.84M |
| Aug 25, 2026 | $631.01 | $647.00 | $618.0303 | $628.15 | 1.54M |
| Aug 24, 2026 | $630.00 | $630.00 | $615.97 | $628.74 | 1.73M |
| Aug 21, 2026 | $626.48 | $629.51 | $616.27 | $629.27 | 1.56M |
| Aug 20, 2026 | $609.85 | $634.70 | $607.37 | $627.55 | 2.75M |
| Aug 19, 2026 | $595.11 | $620.475 | $594.995 | $613.54 | 2.51M |
| Aug 18, 2026 | $588.87 | $592.22 | $584.86 | $589.04 | 1.72M |
| Aug 17, 2026 | $582.55 | $592.32 | $580.00 | $585.51 | 887.3K |
| Aug 14, 2026 | $592.11 | $594.74 | $587.51 | $588.29 | 1.06M |
| Aug 13, 2026 | $606.29 | $606.75 | $593.39 | $595.89 | 1.45M |
| Aug 12, 2026 | $599.21 | $604.19 | $595.00 | $603.01 | 1.53M |
| Aug 11, 2026 | $599.99 | $606.21 | $594.81 | $605.00 | 1.66M |
| Aug 10, 2026 | $588.53 | $599.69 | $588.53 | $599.69 | 1.86M |
| Aug 7, 2026 | $578.00 | $594.26 | $574.7679 | $594.00 | 2.21M |
| Aug 6, 2026 | $576.80 | $580.31 | $569.63 | $580.02 | 1.72M |
The latest Smart Investors Daily articles mentioning TMO.
TMO research
Company profile and research snapshot.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | CLSA | Outperform | — |
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
| Jul 27, 2026 | Piper Sandler | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.
Yahoo · Sep 4, 2026
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher
Yahoo · Sep 3, 2026
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Yahoo · Sep 2, 2026
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. shares closed at $618.43, reflecting a daily decline of approximately 1.05%, per SID market data. Despite the session's pullback, the stock has demonstrated solid momentum over recent periods, gaining 7.75% over the past month and 28.4% over the trailing three months. Year-over-year performance, however, remains more modest at 6.25%, suggesting the bulk of recent gains represent a recovery from prior weakness. Technically, the stock trades well above both its 50-day moving average of $566.05 and its 200-day moving average of $528.05, indicating a sustained uptrend according to Massive/Polygon data. The 14-day RSI sits at 56.2, positioning the stock in neutral territory without overbought or oversold signals. Average daily trading volume stands at approximately 2.05 million shares, while the company's beta of 0.902 indicates slightly lower volatility relative to the broader market. Market capitalization currently totals approximately $219.4 billion.
Thermo Fisher Scientific currently trades at a price-to-earnings ratio of 33.30, positioning it at a premium relative to the broader Healthcare sector, per SID market data. The price-to-book ratio stands at 4.29, reflecting the market's valuation of the company's intangible assets, brand strength, and intellectual property portfolio. The PEG ratio registers at an elevated 577.17, suggesting that the current earnings multiple substantially outpaces near-term expected earnings growth rates, according to SEC filings. The company offers a modest dividend yield of approximately 0.29%, indicating that capital appreciation rather than income distribution remains the primary shareholder return mechanism. With a market capitalization of $219.4 billion, Thermo Fisher ranks among the largest companies in the life sciences and diagnostics industry. The premium valuation metrics reflect the company's dominant market position and recurring revenue streams, though they also indicate limited margin of safety at current price levels relative to fundamental growth expectations.
Thermo Fisher Scientific's composite smart money score stands at 54 out of 100, reflecting a neutral overall signal, per SID market data. Institutional ownership scores a perfect 25 out of 25, indicating exceptionally strong conviction from large asset managers and funds. However, insider activity paints a more cautious picture, scoring just 9.7 out of 25. According to SEC Form 4 filings, there have been 20 insider transactions over the past 90 days, with sells outnumbering buys by a ratio of 9 to 1 — specifically 18 sales versus only 2 purchases. This selling pattern suggests executives and directors have been actively reducing personal exposure at current price levels. Dark pool activity scores 8.5 out of 25, indicating relatively subdued off-exchange institutional accumulation. Congressional trading interest registers at 11.2 out of 25, representing moderate activity among disclosed legislative portfolios. The divergence between robust institutional positioning from 13F filings and persistent insider selling creates a mixed directional signal for TMO shares going forward.
Thermo Fisher Scientific has delivered consecutive earnings beats in its most recently reported quarters, according to company earnings reports. In the most recent quarter reported on July 23, 2026, the company posted earnings per share of $6.03 against a consensus estimate of $5.71, representing a positive surprise of $0.32 or approximately 5.6%. The prior quarter, reported on April 23, 2026, also exceeded expectations with EPS of $5.44 versus estimates of $5.23, delivering a $0.21 upside surprise. Looking ahead, analysts project earnings of $5.71 per share for the upcoming quarter with results expected on July 22, 2026, and $5.29 per share for the following period anticipated on April 22, 2026, per analyst estimates. The pattern of consistent beats suggests management has maintained operational discipline and effective cost management. The forward estimates imply relatively stable sequential earnings expectations, aligning with the company's historically steady performance trajectory across its diversified life sciences portfolio.
Wall Street consensus on Thermo Fisher Scientific leans constructive, with the majority of recent analyst actions reflecting positive or neutral stances, per SID consensus data. On September 3, 2026, CLSA initiated coverage with an Outperform rating, adding a fresh bullish voice to the coverage universe. Morgan Stanley maintained its Overweight rating on July 27, 2026, reaffirming confidence in the company's growth trajectory, according to Wall Street analyst reports. On the same date, Piper Sandler maintained a Neutral position. Barclays reiterated its Overweight rating on July 24, 2026, while RBC Capital held its Sector Perform stance on the same day. Of the five most recent analyst actions, three carry bullish designations — two Overweight ratings and one Outperform — while two maintain neutral positions. No analyst among recent coverage has issued a bearish rating or downgrade, suggesting broad institutional confidence in the company's fundamental outlook. The absence of any negative revisions is notable given the stock's premium valuation multiples.
The latest Smart Investors Daily articles mentioning TMO.
